arrow
Back
S

Sherene Loi

The University of Melbourne

126H-index
1.2KPaper Count
7.8WCitation Count
Published Papers 383
Publication Date
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial
err2026-07-27
err0
errOAAI
errSteven David; Peter Savas; Shankar Siva; Mathias Bressel; Michelle White; Bronte Nikolic; Michael W. Neeson; Shane White; Gavin Marx; Robyn Cheuk; Michelle Grogan; Maria Farrell; Jessica Foudoulis; Paul J. Neeson; Sherene Loi
errShare
errSave
Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib–fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer
err2026-05-27
err0
errOAAI
errS.-A. Im; K. Kalinsky; K.L. Jhaveri; S. Loibl; N. Turner; C. Saura; P. Schmid; S. Loi; E. Hamilton; N. Karadurmus; S. Wang; A.A. Awan; E.M. Ciruelos; C.-F. Chung; E. Thanopoulou; N. Shankar; S. Lim; Y. Jin; C. Song; D. Juric
errShare
errSave
Making sense of TILs: recommendations for morphological assessment of tumour-infiltrating lymphocytes in gastro-oesophageal carcinoma
err2026-02-05
err0
errOAAI
errYlva A Weeda; Roberto Salgado; Filip van Herpe; Daniel Sur; Michael Vieth; Sherene Loi; Ahmad P Tafti; Hardas Alexandros; Akira I Hida; Amarpreet Bhalla; Andrey I Khramtsov; Anna Ehinger; Atsushi Tanaka; Balazs Acs; Caner Ercan; Cornelia M Focke; Daniel Ehinger; Dan Huang; Galina F Khramtsova; Haruto Nishida; Nianyi Li; Nickolas Littlefield; Sanna Steen; Selim Sevim; Shin Ichihara; Shinnosuke Morikawa; Stefan Michiels; Thomas Papathomas; Toshihiro Haga; Qiangqiang Gu; Weiqi Sheng; Hoel Kervadec; Hugo M Horlings; Francisco Sanchez-Vega; Yelena Y Janjigian; Myriam Chalabi; Hanneke W M van Laarhoven; Liudmila L Kodach; Sybren L Meijer
errShare
errSave
Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer
err2026-02-03
err0
PREAI
errSoraia Lobo-Martins; Stephen J. Luen; Martine Piccart; Sherene Loi
errShare
errSave
Antigen reactivity defines tissue-resident memory and exhausted T cells in tumors
err2025-12-29
err0
errOAAI
errThomas N. Burn; Jan Schröder; Luke C. Gandolfo; Maleika Osman; Elanor N. Wainwright; Enid Y. N. Lam; Keely M. McDonald; Rachel B. Evans; Shihan Li; Daniel Rawlinson; Lachlan Dryburgh; Ali Zaid; Zoltan Maliga; Dominick Schienstock; Philippa Meiser; Hyun Jae Lee; Hongjin Lai; Marcela L. Moreira; Pirooz Zareie; Louis H-Y. Lee; Lutfi Huq; Susan N. Christo; Justine J. W. Seow; Keith A. Ching; Stéphane M. Guillaume; Kathy Knezevic; Simone L. Park; Maximilien Evrard; Jason Waithman; Thomas Gebhardt; Scott N. Mueller; Georgina E. Riddiough; Marcos V. Perini; Simon C. H. Tsao; Terence P. Speed; Peter K. Sorger; Sherene Loi; Francis R. Carbone; Stephanie Gras; Timothy S. Fisher; Bas J. Baaten; Mark A. Dawson; Laura K. Mackay
errShare
errSave
Author Correction: Advancing equitable access to innovation in breast cancer
err2025-12-16
err0
errOAAI
errSeamus O’Reilly; Ines Vaz Luis; Virginie Adam; Evangelia D. Razis; Ander Urruticoechea; Amal Arahmani; Eva Carrasco; Boon H. Chua; Judith Bliss; Carolyn Straehle; Theodora Goulioti; Barbro Lindholm; Gustavo Werutsky; Etienne Brain; Philippe L. Bedard; Giuseppe Curigliano; Sherene Loi; Shigehira Saji; David Cameron
errShare
errSave
The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus
err2025-11-24
err0
PREAI
errAndré Pfob; Katja Pinker; Ines Vaz-Luis; Antonio Di Meglio; Maria João Cardoso; Giuseppe Curigliano; Oreste Davide Gentilini; Günther Gruber; Nik Hauser; Jörg Heil; Orit Kaidar-Person; Michael Knauer; Han-Byoel Lee; Sae Byul Lee; Sherene Loi; Meinrad Mannhart; Stella Mastora; Icro Meattini; Rosa Di Micco; Aurelia Noske
errShare
errSave
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02
err2025-11-17
err0
errOAAI
errS.A. Hurvitz; S. Loi; J. O’Shaughnessy; A.F.C. Okines; S.M. Tolaney; J. Sohn; C. Saura; X. Zhu; D. Cameron; T. Bachelot; E. Hamilton; G. Curigliano; A.C. Wolff; N. Harbeck; N. Masuda; L. Vahdat; K. Zaman; F. Valdes-Albini; M. Block; T. Pluard
errShare
errSave
Parity and lactation induce T cell mediated breast cancer protection
errNature
IF48.5
err2025-10-20
err0
PREAI
errBalaji Virassamy; Franco Caramia; Peter Savas; Michael A. Harris; Jia-Wern Pan; Jianan Wang; Emmaline Brown; Megan M. R. O’Malley; Courtney T. van Geelen; Michael Hun; Thomas N. Burn; Sneha Sant; Jamieson D. Ballan; Jasmine Kay; Luis E. Lara Gonzalez; Kylie Clarke; Han Xian Aw Yeang; Rejhan Idrizi; Metta Jana; Damon J. Challice; Roberto Salgado; Heather Thorne; Cathie Poliness; Sophie Nightingale; Soo-Hwang Teo; Terence P. Speed; Jane Visvader; Paul J. Neeson; Phillip K. Darcy; Laura K. Mackay; Sherene Loi
errShare
errSave
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival☆
err2025-10-17
err0
errOAAI
errJ. Crown; D. Stroyakovskii; D.A. Yardley; C.-S. Huang; P.A. Fasching; A. Bardia; S. Chia; S.-A. Im; M. Martin; B. Xu; C.H. Barrios; M. Untch; R. Moroose; S.A. Hurvitz; G.N. Hortobagyi; D.J. Slamon; F. Visco; G. Spera; J.P. Zarate; D. Halligan; Z. Li; S. Loi
errShare
errSave
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer
err2025-10-08
err0
errOAAI
errH.J. Burstein; G. Curigliano; M. Gnant; S. Loibl; M.M. Regan; S. Loi; C. Denkert; P. Poortmans; D. Cameron; B. Thurlimann; W.P. Weber
errShare
errSave
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy
err2025-10-02
err0
errOAAI
errJavier Cortes; Oleg Lipatov; Seock-Ah Im; Anthony Goncalves; Keun Seok Lee; Peter Schmid; Kenji Tamura; Laura Testa; Shoichiro Ohtani; Nadia Harbeck; Sherene Loi; Roberto Salgado; Vassiliki Karantza; Jaime Mejia; Razvan Cristescu; Andrey Loboda; Michael Nebozhyn; Petar Jelinic; Lingkang Huang; Eric P. Winer
errShare
errSave
Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial
err2025-10-01
err0
PREAI
errLoi, Sherene; Salgado, Roberto; Curigliano, Giuseppe; Ivan Romero Diaz, Roberto; Delaloge, Suzette; Rojas Garcia, Carlos Ignacio; Kok, Marleen; Saura, Cristina; Harbeck, Nadia; Mittendorf, Elizabeth A.; Yardley, Denise A.; Suarez Zaizar, Alberto; Caminos, Facundo Rufino; Ungureanu, Andrei; Reinoso-Toledo, Joaquin G.; Guarneri, Valentina; Egle, Daniel; Ades, Felipe; Pacius, Misena; Chhibber, Aparna; Chandra, Rajalakshmi; Nathani, Raheel; Spires, Thomas; Qun Wu, Jenny; Pusztai, Lajos; Mcarthur, Heather
errShare
errSave
Baseline tumour burden and prognosis in breast cancer treated with immune checkpoint inhibitors
err2025-09-25
err0
errOAAI
errJulia Dixon-Douglas; Lauren C. Brown; Kate Moodie; Courtney T. Van Geelen; Steven David; Prudence A. Francis; Peter Savas; Sherene Loi
errShare
errSave
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT
errCancer
IF5.1
err2025-09-23
err0
PREAI
errKarin Ribi PhD; Bernard F. Cole PhD; Gini F. Fleming MD; Barbara A. Walley MD; Prudence A. Francis MD; Ehtesham Abdi MD; Harold J. Burstein MD, PhD; Kit L. Cheng MD; Stephen K. L. Chia MD, FRCP; Shaker R. Dakhil MD; Nancy E. Davidson MD; Stephen A. Della-Fiorentina MD; Ashley E. Frith MD; Ellis Levine MD; Sasha Lupichuk MD; Kathleen Pritchard MD; Muhammad Salim MD; Vered Stearns MD; Josephine Stewart MD; Vicente Valero MD; Andre van der Westhuizen MD; Olivia Pagani MD; Sherene Loi MD, PhD; Marco Colleoni MD; Richard D. Gelber PhD; Aron Goldhirsch MD; Alan S. Coates MD; Meredith M. Regan ScD; Jürg Bernhard PhD
errShare
errSave
Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Breast Cancer
err2025-07-21
err0
errOAAI
errMichelle Li; François Panet; Vittoria Barberi; Roberto Salgado; Mafalda Oliveira; Sherene Loi
errShare
errSave
Advancing equitable access to innovation in breast cancer
err2025-07-10
err0
errOAAI
errSeamus O’Reilly; Ines Vaz Luis; Virginie Adam; Evangelia D. Razis; Ander Urruticoechea; Amal Arahmani; Eva Carrasco; Boon H. Chua; Judith Bliss; Carolyn Straehle; Theodora Goulioti; Barbro Lindholm; Gustavo Werustsky; Etienne Brain; Philippe L. Bedard; Giuseppe Curigliano; Sherene Loi; Shigehira Saji; David Cameron
errShare
errSave
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
err2025-04-17
err0
errOAAI
errPeter Schmid; Mafalda Oliveira; Joyce O’Shaughnessy; Massimo Cristofanilli; Stephanie L. Graff; Seock-Ah Im; Sherene Loi; Shigehira Saji; Shusen Wang; David W. Cescon; Tina Hovey; Agata Nawrot; Karson Tse; Petra Vukovic; Giuseppe Curigliano
errShare
errSave
errShare
errSave